deltatrials
Completed PHASE3 NCT00049452

Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy After Surgery For Early Stage Breast Cancer

A Randomized, Placebo Controlled Trial Of Zoledronic Acid For The Prevention Of Bone Loss In Premenopausal Women With Early Stage Breast Cancer

Sponsor: Herbert Irving Comprehensive Cancer Center

Conditions Breast Cancer Osteoporosis
Interventions zoledronic acid
Updated 5 times since 2017 Last updated: Jan 3, 2014 Started: Dec 31, 2001 Completion: Aug 31, 2008

This PHASE3 trial investigates Breast Cancer and Osteoporosis and is currently completed. Herbert Irving Comprehensive Cancer Center leads this study, which shows 5 recorded versions since 2001 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Dec 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Herbert Irving Comprehensive Cancer Center
  • National Cancer Institute (NCI)
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • New York, United States
  • • Paramus, United States
  • • Stamford, United States